FR
Fredun Pharmaceuticals Ltd (FREDUN)
₹1,363.20
Mkt cap
₹2,156 Cr
P/E ratio
48.50
P/B
8.02
Div yield
0.02%
ROE
15.80%
ROCE
21.50%
EPS (TTM)
₹28.11
Book value
₹170
52W range
1,195–1,590
Sector
Healthcare
Price history
Previous close
Incorporated in 1987, Fredun Pharmaceuticals Ltd manufactures & exports healthcare and pharmaceuticals products [1]
NSE FREDUNBSE 539730
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
−14.26% from high₹1,363
₹1,195+14.06% from low₹1,590
Current
₹1,363.20
Prev close
₹1,355.20
Day
+0.59%
Price performance
1D
+0.59%
1W
+0.49%
1M
−9.47%
3M
—
6M
—
1Y
—
YTD
−7.52%
Financials
Revenue, profit & margin
P/E ratio
48.5×
FREDUN is 40% above the sector median of 34.6×
FREDUN48.5×
Sector median34.6×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 62 | 82 | 87 | 118 | 79 | 107 | 103 | 167 | 120 | 145 | 161 | 213 | 228 | |
| Expenses | 54 | 72 | 76 | 107 | 68 | 93 | 89 | 150 | 103 | 123 | 135 | 184 | 195 | |
| Operating Profit | 8 | 10 | 11 | 11 | 10 | 14 | 13 | 17 | 17 | 22 | 26 | 29 | 33 | |
| OPM % | 12% | 12% | 12% | 9% | 13% | 13% | 13% | 10% | 14% | 15% | 16% | 14% | 14% | |
| Other Income | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | |
| Interest | 3 | 3 | 4 | 4 | 4 | 5 | 5 | 8 | 7 | 8 | 11 | 14 | 9 | |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 4 | |
| Profit before tax | 4 | 6 | 6 | 6 | 6 | 8 | 7 | 8 | 9 | 13 | 14 | 12 | 21 | |
| Tax % | 41% | 32% | 27% | 13% | 25% | 44% | 25% | 12% | 25% | 25% | 25% | 4% | 36% | |
| Net Profit | 2 | 4 | 4 | 5 | 4 | 4 | 5 | 7 | 7 | 10 | 10 | 11 | 13 | |
| EPS in Rs | 1.75 | 2.79 | 2.99 | 3.59 | 2.91 | 3.01 | 3.75 | 4.98 | 4.77 | 6.85 | 6.51 | 6.75 | 7.98 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Jul 202644.57%Promoter
Promoters44.57%
FIIs1.06%
DIIs2.94%
Public51.43%0.02
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,837.30 | 34.90 | 4,40,830 | 0.87% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| Divi's Lab. | ₹9,375.00 | 83.54 | 2,48,877 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,840.00 | 82.51 | 1,84,098 | 0.79% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| Zydus Lifesci. | ₹1,160.00 | 23.77 | 1,15,710 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Cipla | ₹1,394.50 | 31.48 | 1,12,656 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Laurus Labs | ₹1,954.00 | 96.56 | 1,05,577 | 0.10% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| Aurobindo Pharma | ₹1,734.00 | 26.39 | 99,771 | 0.23% | 1,032 | +28.11% | 9,150 | +16.30% | 12.86% |
| Fredun Pharma | ₹1,303.50 | 48.50 | 2,156 | 0.02% | 13 | +94.53% | 228 | +90.45% | 21.49% |
| Median: 158 Co. | ₹433.90 | 34.56 | 2,205 | 0.08% | 13 | +29.57% | 164 | +18.57% | 14.96% |
Filings
Annual reports15
Concall transcripts13
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Allotment 16 Sep - Fredun Pharmaceuticals allotted 2,71,200 equity shares on 16 Sept 2026 after 90,400 warrant conversions.Board Meeting Outcome for Allotment Of 2,71,200 Equity Shares To Non-Promoter Upon Conversion Of Warrants Into Equity Shares 16 Sep - Board allotted 2,71,200 equity shares on 16 September 2026 after warrant conversion.Announcement under Regulation 30 (LODR)-Press Release / Media Release (Revised) 15 Sep - Furlicks expands pet wellness offerings6 to 22 SKUs.Announcement under Regulation 30 (LODR)-Press Release / Media Release 15 Sep - Fredun Pharmaceuticals expands Furlicks pet wellness line6 to 22 SKUs.Announcement under Regulation 30 (LODR)-Press Release / Media Release 8 Sep - Fredun Pharmaceuticals acquires Furlicks from USV, plans 12 SKUs first phase and 32 later.